abstract |
The invention relates to rivastigmine as a free base or in the form of a pharmaceutically acceptable salt for use in a method of preventing, treating or delaying the development of dementia or Alzheimer's disease, wherein rivastigmine is administered in a Transdermal Therapeutic System and the starting dose is greater than 3 mg. rivastigmine per day. |